Mavacamten (CAMZYOS) is a first-in-class, orally active, selective cardiac myosin allosteric modulator, also known as a selective allosteric and reversible inhibitor of cardiac myosin. It mainly targets the core pathophysiological mechanism of hypertrophic cardiomyopathy (HCM) and reduces the symptoms of excessive cardiac contraction in patients by regulating the excessively strong sarcomere contraction in hypertrophic cardiomyopathy.

Is Mavacamten (CAMZYOS) available in China? How to buy it?

Mavacamten is currently available in China. For patients in need of this medicine, it can be purchased directly through hospital pharmacies or large chain pharmacies. Mavacamten is a prescription drug, and patients should hold a prescription issued by a doctor when purchasing, and buy it with the prescription.

When purchasing and using mavacamten, patients should strictly follow the doctor's guidance and advice. The doctor will formulate a personalized treatment plan according to the patient's specific condition, physical status, as well as the characteristics and interactions of the drug. Patients should take the medicine according to the dosage and frequency prescribed by the doctor, and must not increase or decrease the dosage by themselves, let alone stop or change the medicine at will.

Medication for special populations of Mavacamten (CAMZYOS)?

For specific populations, special attention should be paid to the potential risks of medication when using mavacamten. The following are the medication recommendations for pregnant women, lactating women, and women and men of reproductive potential:

Pregnant women

The use of mavacamten by pregnant women may cause harm to the fetus. At present, there are no human data on the use of mavacamten during pregnancy to evaluate the risk of major birth defects, miscarriage, or other adverse maternal and infant outcomes to the fetus. Pregnant women should avoid using this drug.

Lactating women

The presence of mavacamten in human or animal milk and its impact on breastfed infants are unknown, and the impact of mavacamten on milk production is also unknown. When considering the benefits of breastfeeding and the mother's clinical need for mavacamten, the potential adverse effects on the breastfed child should be weighed.